medigraphic.com
ISSN 1561-2988 (Print)

2012, Number 2

<< Back Next >>

Rev Cubana Farm 2012; 46 (2)

Pathogenic molecular processes of atherosclerosis and therapeutic alternatives for control

Delgado RL, Vázquez LAM, Martínez-Sánchez G

Language: Spanish
References: 65
Page: 267-280
PDF size: 77.99 Kb.


ABSTRACT

Atherosclerosis is a chronic vascular disease which affects bifurcations of major arteries. Atherosclerosis-associated cardiovascular diseases represent the first cause of mortality in the western world. The physiopathology of atherosclerosis associates a variety of molecular and cellular complex events, which are not completely understood. However, some hypothesis have been postulated to explain the pathogenic events during atherogenesis. The objective of the present article is to offer an updating on the principal molecular events during the atherosclerosis development and therapeutic alternatives for its treatment and control. To this end, a literature review was made in MEDLINE database, which covered the scientific publications of the last 10 years. The complexity of this illness was analyzed in depth and it was demonstrated that there was not any completely effective therapy to treat it.


REFERENCES

  1. Paim BA, Velho JA, Castillo RF, Oliveira H, Vercesi AE. Oxidative stress in hypercholesterolemic LDL (low density lipoprotein) receptor knockout mice is associated with low content of mitochondrial NADP-linked substrates and is partially reversed by citrate replacement. Free Radic Biol Med. 2008;44:444-51.

  2. Shalhoub J, Falck-Hansen MA, Davies AH, Monaco C. Innate immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm 2011;8(1):9. Available from: http://www.journal-inflammation.com/content/8/1/9

  3. Tavori H, Aviram M, Khatib S, Musa R, Nitecki S, Hoffman A, et al. Human carotid atherosclerotic plaque increases oxidative state of macrophages and low density lipoproteins, whereas paraoxonase (PON1) decreases such atherogenic effects. Free Radic Biol Med. 2009;46:607-15.

  4. Steinberg D, Parthasarathy S, Crew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low density lipoprotein that increase its atherogenecity. N Engl J Med. 1989;320:915-24.

  5. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation. 2007;116:1832-44.

  6. Ross R. Atherosclerosis-and inflammatory disease. N Engl J Med. 1999;340:115-26.

  7. Wick G, Perschinka H, Milloning G. Atherosclerosis as an autoimmune disease: an update. TRENDS Immunol. 2001;22:665-9.

  8. Stemme S, Rymo L, Hansson GK. Polyclonal origin of T lymphocytes in human atherosclerotic plaques. Lab Invest. 1991;65:654-60.

  9. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:17-38.

  10. Hessler JR, Robertson AL Jr, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 1979;32:213-29.

  11. Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 1984;4:357-64.

  12. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low-density lipoprotein previously incubated with cultured endothelial cells: recognition by receptor for acetylated low-density lipoproteins. Proc Natl Acad Sci USA. 1981;78:6499-503.

  13. Streinbrecher VP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc Natl Acad Sci USA. 1984;81:3883-7.

  14. Skalén K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002; 417:750-4.

  15. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta. 2006;367:36-47.

  16. Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis. 2008;201:17-32.

  17. Xu F, Ji J, Li L, Chen R, Hu W. Activation of endothelial fibroblasts contributes to the early development of atherosclerosis: a novel hypothesis that complements the "Response-to-injury hypothesis" and the "Inflammation hypothesis". Med Hypotheses. 2007;69:908-12.

  18. Xu F, Ji L, Chen R, Hu W. JE mRNA expression and MCP-1 expression in the adventitial fibroblasts of aortic root in ApoE knockout mice before the intimal lesion formation. Atherosclerosis Supp. 2006;7:203.

  19. Federico E, Patrick J. The reactive adventitia fibroblast oxidase in vascular function. Atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:1962-71.

  20. Gao PJ, Li Y, Sun AJ, Lin JJ, Ji KD, Zhang YZ, et al. Differentiation of vascular myofibroblasts induced by transforming growth factor beta1 requires the involvement of protein kinase C alpha. J Mol Cell Cardiol. 2003;35:1105-12.

  21. Hansson GK, Libby P. The immune response in atherosclerosis: a doubled edged sword. Nat Rev Immunol. 2006;6:508-18.

  22. Mackay IR, Leskovsek N, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimm. 2008;30:5-11.

  23. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011;108:235-48.

  24. Xiao Q, Mandal K, Schett G. Association of serum-soluble heat shock protein 60 with carotid atherosclerosis. Stroke. 2005;36:2571-6.

  25. Zhu J, Katz RJ, Quyummi AA. Association of serum antibodies to heat-shock protein 65 with coronary calcification levels. Suggestion of pathogen-triggered autoimmunity in early atherosclerosis. Circulation. 2004;109:36-41.

  26. Alard JE, Dueymes M, Youinou P, Jamin C. Modulation of endothelial cell damages by anti-HSP60 autoantibodies in systemic autoimmune diseases. Autoimm Rev 2007;6:438-43.

  27. Riganó R, Profumo E, Buttari B. Heat shock proteins and autoimmunity in patients with carotid atherosclerosis. Ann NY Acad Sci. 2007;1107:1-10.

  28. Zhang G, Ghosh S. Toll-like receptor-mediated NF-kB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest. 2001;107:13-9.

  29. Schoenfeld Y. Atherosclerosis as autoimmune condition. Harefuah. 2001;140:720-2.

  30. Schonferr E, Zhao B, Hausser H, Muller M, Langer C, Wagner WD, et al. Lipoprotein lipase-mediated interactions of small proteoglycans and low-density lipoprotein. Eur J Cell Biol. 2000;79:689-96.

  31. Lemire JM, Braun KR, Maurel P, Kaplan ED, Schwartz SM, Weight TN. Versican/PG-M isoforms in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1630-9.

  32. Schaefer L, Schaefer RM. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res. 2009; doi: 10.1007/s00441-009-0821-y.

  33. Wight TN, Merriles MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res. 2004;94:1158-67.

  34. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011;145:341-55.

  35. Delgado L, Martínez-Sánchez G. Nuevos enfoques sobre el papel de las lipoproteínas plasmáticas en las enfermedades de origen aterotrombótico. Rev Cubana Farm. 2010;44:235-48.

  36. Jones DP. Redefining oxidative stress. Antioxid Redox Signal. 2006;8:1865-79.

  37. Singh U, Jalial I. Oxidative stress and atherosclerosis. Pathophysiology. 2006;13:129-42.

  38. León OS, Martínez G, Candelario EJ, García I, Bilbao T, Ledesma L. Balance antioxidante- prooxidante: salud y enfermedad. La Habana: Editorial Ciencias Médicas; 2005. p. 60-65, 84.

  39. Habets KLL, van Puijvelde GHM, van Duivenvoorde LM, van Wanrooij EJA, de Vos P, Tervaert JWC. Vaccination using oxidized low-densitylipoprotein-pulsed dendritic cells reducesatherosclerosis in LDL receptor-deficient mice. Cardiovasc Res. 2010;85:622-30.

  40. Larsson DA, Baird S, Nyahlah JD, Yuan XM, Li W. Oxysterol mixtures, in atheroma-relevant proportions, display synergistic and proapoptotic effects. Free Radic Biol Med. 2006;41:902-10.

  41. Maziére C, Maziére JC. Activation of transcription factors and gene expression by oxidized-low density lipoproteins. Free Radic Biol Med. 2009;46:127-37.

  42. Gu Q, Bowden GT, Normolle D, Sun Y. SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IkappaB-alpha/NFkB. J Cell Biol. 2007;39:1009-23.

  43. Serkkola E, Hurme M. Synergism between protein-kinase C and c-AMP dependent pathways in the expression of the interleukin-1 beta gene is mediated via the activator protein-1 (AP-1) enhancer activity. Eur J Biochem. 1993;213:243-9.

  44. Chen Y, Currie RW. Heat shock treatments suppress angiotensin II-induced AP-1 and SP-1 and stimulate Oct-1 DNA-binding activity in heart. Inflamm Res. 2005;54:338-43.

  45. Ma Q. Transcriptional responses to oxidative stress: pathological and toxicological implications. Pharmacol Therap. 2010;125:376-93.

  46. Ferreira V, Van Dijk KW, Groen AK, Vos RM, Van der Kaa J, Gijbels MJ et al. Macrophage-specific inhibition of nuclear factor-kappa B activation reduces foam cells formation. Atherosclerosis. 2007;192:283-90.

  47. Inoue T, Node K. Vascular failure: a new clinical entity for vascular disease. J Hypertens. 2006;24:2121-30.

  48. Obrosova IG. Peroxynitrite and cardiomyocyte cell death: An evolving story. Free Radic Biol Med. 2006;41:866-8.

  49. Szabo G, Bahrle S. Role of nitrosative stress and poly (ADP-ribose) polymerase activation in myocardial reperfusion injury. Curr Vasc Pharmacol. 2005;3:215-20.

  50. Rubbo H, O´Donell V. Nitric oxide peroxynitrite and lipooxygenase in atherogenesis: mechanistic insights. Toxicology. 2005;208:305-17.

  51. Denicola A, Radi R. Peroxynitrite and drug-dependent toxicity. Toxicology. 2005;208:273-88.

  52. Levrand S, Vannay-Bouchiche C, Pesse B, Pacher P, Feihl F, Waeber, et al. Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med. 2006;41:886-95.

  53. Delgado L, Martínez-Sánchez G, Díaz A. Determinación de marcadores de estrés oxidativo en pacientes con enfermedades cardiovasculares. Acta Bioquím Clín Latinoam. 2009;43:307-13.

  54. Katsiki N, Manes C. Is there a role for supplemented antioxidants in the prevention of the atherosclerosis? Clin Nutr. 2009;28:3-9.

  55. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don´t throw out the baby with the bath water. Circulation. 2003;107:926-8.

  56. Halliwell B. The wanderings of a free radical. Free Radic Biol Med. 2010; 46:531-42.

  57. Tardif JC, Coté G, Lespérance J, Bourassa M, Lambert J, Doucet S, et al. Probucol and multivitamins in the prevention of reestenosis after coronary angioplasty: multivitamins and Probucol study group. N Engl J Med. 1997;337:365-72.

  58. Cook NR, Albert CM, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women. Arch Intern Med. 2007;167:1610-8.

  59. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analyses. JAMA. 2007;297:842-57.

  60. Ait-Oufella H, Herbin O, Bousaziz JD, Binder CJ, Uyttenhove C, Laurans L, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010;207:1579-87.

  61. Delgado L. Role of the immunological system in the initiation and progression of atherosclerosis. Pharmacologyonline. 2010;2:282-97.

  62. Steffens S, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, et al. Shortterm treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation. 2006;114:1977-84.

  63. De Jager SCA, Kuiper J. Vaccination strategies in atherosclerosis. Thromb Haemost. 2011;106:796-803.

  64. Den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis. 2010;209:314-20.

  65. Wanrooij EJ, Puijvelde GH, Vos P, Yageta H, Berkeld TJ, Kuiper J. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:204-10.




2020     |     www.medigraphic.com